CTLA4 and melanoma: Convincing clinical evidence of synergy from CTLA-4/PD-1 co-inhibition in melanoma [116], kidney cancer [117] and NSCLC [118] has led to the understanding that concurrent targeting of multiple immune checkpoints leads to an increased magnitude and depth of anti-tumour immune responses across malignancies.